| 1. IDENTIFICATION & BASIC DESCRIPTION |
|
Cohort name
|
| |
Milan Policlinico Healthcare Workers (POLIMI-HCW)
|
|
Country
|
| |
|
|
Name
|
| |
Dario Consonni
|
|
Institution
|
| |
Epidemiology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
|
|
Email
|
| |
dario.consonni@unimi.it
|
|
Phone
|
| |
+390255032634
|
|
Personal website
|
| |
https://www.policlinico.mi.it/i-nostri-professionisti/profilo/1027/consonni-dario
|
|
Name of committee
|
| |
Policlinico Hospital Review Board
|
|
Contact Principal Investigator (name)
|
| |
Dario Consonni
|
|
Participation in pooled analyses
|
| |
- The cohort is potentially interested in participating in pooled analyses of (European) occupational cohort studies (note pooled analyses also includes remote decentralized analyses that would not require any transfer of primary data as well as meta-analyses).
|
|
Main aim of cohort, please briefly describe the main objectives of the cohort
|
| |
To examine occurrence of SARS-CoV-2 infection among healthcare workers
|
|
Study design (please select as many as appropriate)
|
| |
|
|
Source population (please select as many as appropriate)
|
| |
- Industry / occupation -based
|
|
Comparators (please select as many as appropriate)
|
| |
- Internal study population
|
|
Inclusion criteria
|
| |
Hospital employed
|
|
Year(s) of enrollment
|
| |
|
|
Enrollment
|
| |
Ongoing
|
|
Age range at entry (subcohort)
|
| |
| Minimum |
Maximum |
Mean |
Please describe |
| 20 |
75 |
|
|
|
|
Men at enrollment
|
| |
1500
|
|
Women at enrollment
|
| |
3500
|
| 2. OUTCOME FOLLOW-UP |
|
Type of data for outcome follow-up (please select as many as appropriate)
|
| |
|
|
Specify: Other
|
| |
- SARS-CoV-2 nasopharyngeal swab and serum antibodies
|
| 3. OCCUPATIONAL EXPOSURES |
|
Source of exposure data collected (please select as many as appropriate)
|
| |
- Questionnaire, Personal (Self-reporting or interview)
- Job-employment records
|
|
Occupational history/time frame
|
| |
Current, at enrollment
|
|
Occupational coding performed
|
| |
No
|
| 4. OUTCOMES EVALUATED |
|
Baseline - type of outcome data collected (select more than one if applicable)
|
| |
|
|
Specify: Biomarker
|
| |
SARS-CoV-2 RNA measured via RT-PCR + serum IgG antibodies
|
|
Follow-up - type of outcome data collected (select more than one if applicable)
|
| |
|
|
Specify: Biomarker
|
| |
SARS-CoV-2 RNA measured via RT-PCR + serum IgG antibodies
|
|
Outcome type (please select as many as appropriate)
|
| |
|
|
Diagnostic groups based on ICD10
|
| |
- B Viral infections, type of microorganisms*
|
|
B Viral infections, type of microorganisms
|
| |
- Other viral infections, please state
|
|
B Viral infections, type of microorganisms | Other (specify)
|
| |
SARS-CoV-2
|
|
Other health related outcomes
|
| |
|
|
Specify: Other
|
| |
PTSD
|
| 5. BIOLOGICAL SAMPLES & ANALYSIS |
|
Biological samples collected
|
| |
|
|
Specify: Other
|
| |
Nasopharyngeal mucus
|
|
Biological processing
|
| |
|
|
Genetic and other lab analyses
|
| |
|
|
Specify: Biomarkers
|
| |
SARS-CoV-2 IgG serum antibodies
|
| 6. Other Information |
|
|
| |
- Anthropometry
- Demographics
- Medical history
- Smoking
|
|
Possibility for linkage to data registries/data enrichment via data linkage
|
| |
|
